A detailed history of Nuveen Asset Management, LLC transactions in Voyager Therapeutics, Inc. stock. As of the latest transaction made, Nuveen Asset Management, LLC holds 108,789 shares of VYGR stock, worth $624,448. This represents 0.0% of its overall portfolio holdings.

Number of Shares
108,789
Previous 108,789 -0.0%
Holding current value
$624,448
Previous $860,000 26.05%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 09, 2024

BUY
$7.42 - $10.54 $144,126 - $204,728
19,424 Added 21.74%
108,789 $860,000
Q4 2023

Feb 14, 2024

BUY
$6.28 - $8.81 $5,903 - $8,281
940 Added 1.06%
89,365 $754,000
Q2 2023

Aug 14, 2023

BUY
$6.94 - $13.99 $613,669 - $1.24 Million
88,425 New
88,425 $1.01 Million
Q2 2021

Aug 16, 2021

SELL
$3.94 - $5.44 $352,239 - $486,341
-89,401 Closed
0 $0
Q1 2021

May 17, 2021

SELL
$4.61 - $9.04 $16,969 - $33,276
-3,681 Reduced 3.95%
89,401 $421,000
Q4 2020

Feb 16, 2021

SELL
$7.15 - $12.28 $1.3 Million - $2.23 Million
-181,223 Reduced 66.07%
93,082 $665,000
Q3 2020

Nov 16, 2020

SELL
$10.01 - $13.75 $1.33 Million - $1.83 Million
-133,134 Reduced 32.68%
274,305 $2.93 Million
Q2 2020

Aug 14, 2020

SELL
$8.05 - $14.21 $58,845 - $103,875
-7,310 Reduced 1.76%
407,439 $5.14 Million
Q1 2020

May 14, 2020

SELL
$6.8 - $14.66 $1,523 - $3,283
-224 Reduced 0.05%
414,749 $3.79 Million
Q4 2019

Feb 14, 2020

SELL
$12.82 - $16.85 $1.37 Million - $1.8 Million
-107,086 Reduced 20.51%
414,973 $5.79 Million
Q3 2019

Nov 14, 2019

BUY
$16.31 - $28.29 $4.32 Million - $7.48 Million
264,574 Added 102.75%
522,059 $8.99 Million
Q2 2019

Aug 15, 2019

BUY
$19.18 - $27.88 $4.94 Million - $7.18 Million
257,485 New
257,485 $7.01 Million

Others Institutions Holding VYGR

About Voyager Therapeutics, Inc.


  • Ticker VYGR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 38,647,600
  • Market Cap $222M
  • Description
  • Voyager Therapeutics, Inc., a gene therapy company, focuses on the development of treatments and next-generation platform technologies. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1 clinical trial for the treatment of Parkinson's disease. Its preclinical programs comprise VY-SOD102 for the treatment of amyo...
More about VYGR
Track This Portfolio

Track Nuveen Asset Management, LLC Portfolio

Follow Nuveen Asset Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Nuveen Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Nuveen Asset Management, LLC with notifications on news.